SE0203410D0 - New use - Google Patents

New use

Info

Publication number
SE0203410D0
SE0203410D0 SE0203410A SE0203410A SE0203410D0 SE 0203410 D0 SE0203410 D0 SE 0203410D0 SE 0203410 A SE0203410 A SE 0203410A SE 0203410 A SE0203410 A SE 0203410A SE 0203410 D0 SE0203410 D0 SE 0203410D0
Authority
SE
Sweden
Prior art keywords
vomiting
inhibitor compound
proton pump
pump inhibitor
nausea
Prior art date
Application number
SE0203410A
Other languages
English (en)
Inventor
Ulrich Thissen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203410A priority Critical patent/SE0203410D0/sv
Publication of SE0203410D0 publication Critical patent/SE0203410D0/sv
Priority to AU2003279667A priority patent/AU2003279667A1/en
Priority to PCT/SE2003/001774 priority patent/WO2004045612A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0203410A 2002-11-18 2002-11-18 New use SE0203410D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0203410A SE0203410D0 (sv) 2002-11-18 2002-11-18 New use
AU2003279667A AU2003279667A1 (en) 2002-11-18 2003-11-14 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting
PCT/SE2003/001774 WO2004045612A1 (en) 2002-11-18 2003-11-14 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203410A SE0203410D0 (sv) 2002-11-18 2002-11-18 New use

Publications (1)

Publication Number Publication Date
SE0203410D0 true SE0203410D0 (sv) 2002-11-18

Family

ID=20289602

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203410A SE0203410D0 (sv) 2002-11-18 2002-11-18 New use

Country Status (3)

Country Link
AU (1) AU2003279667A1 (sv)
SE (1) SE0203410D0 (sv)
WO (1) WO2004045612A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20070259933A1 (en) * 2006-05-04 2007-11-08 Xenoport, Inc. Compositions, dosage forms and methods of treating emesis
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
EP3574914B1 (en) 2007-11-13 2021-12-29 ViroPharma Biologics LLC Corticosteroid compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist

Also Published As

Publication number Publication date
WO2004045612A1 (en) 2004-06-03
AU2003279667A1 (en) 2004-06-15
WO2004045612A8 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
MX2007006063A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
TW200505881A (en) Tri(cyclo) substituted amide compounds
ATE341550T1 (de) Quinolinyl-pyrrolopyrazole
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
WO2004006859A3 (en) Platinum compound
EA200600223A1 (ru) Замещённый 2-аминотетралины для лечения депрессии
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
MXPA05007379A (es) Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0514250A (pt) uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
NO20072832L (no) Smertestillende middel
SE0203410D0 (sv) New use
IS7517A (is) Efnasambönd sem nýtast í meðferð við miltisbrandiog hindra banvænan þátt
CA2540102A1 (en) A combination of candesartan and rosuvastatin for the treatment of atherosclerosis
BRPI0507802A (pt) composto, composição, e, método para tratar inflamação ou um distúrbio metabólico
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.